Admin Login      My Saved Results      Contact Us      News & Events FaceBook Twitter YouTube LinkedIn

A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies

Status: Active printPrint Results Email Results Save Results
Cancer Type: Non-Hodgkin Lymphoma NCT ID: NCT01799889
Trial Phases: Phase II Protocol IDs: GS-US-339-0102 (primary)
Eligibility: 18 and over, Male and Female Study Type: Biomarker/Laboratory analysis
Study Sponsor: Gilead Sciences
NCI Full Details:


This study is to evaluate the efficacy, safety, tolerability, and pharmacodynamics of GS-9973. Up to 200 participants will be enrolled who have one of the following hematological tumor types: relapsed or refractory chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), or non-FL indolent non-Hodgkin lymphomas (iNHL; including lymphoplasmacytoid lymphoma/ Waldenström macroglobulinemia [LPL/WM], small lymphocytic lymphoma [SLL], or marginal zone lymphoma [MZL]). If GS-9973 demonstrates promising activity additional participants may be enrolled to evaluate GS-9973 at lower doses, to a maximum of 80 additional participants.